Bonesupport Holding AB (publ)

OM:BONEX Stock Report

Market Cap: SEK 23.7b

Bonesupport Holding Past Earnings Performance

Past criteria checks 1/6

Bonesupport Holding has been growing earnings at an average annual rate of 62.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 36.9% per year. Bonesupport Holding's return on equity is 13.7%, and it has net margins of 11.1%.

Key information

62.2%

Earnings growth rate

63.6%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate36.9%
Return on equity13.7%
Net Margin11.1%
Next Earnings Update25 Feb 2025

Recent past performance updates

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Recent updates

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16
We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06
We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Revenue & Expenses Breakdown

How Bonesupport Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:BONEX Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248149157572
30 Jun 2473528953965
31 Mar 2465626749759
31 Dec 2359124546257
30 Sep 2352221442054
30 Jun 23448-3038354
31 Mar 23382-5134253
31 Dec 22329-6831253
30 Sep 22287-7227953
30 Jun 22257-7124951
31 Mar 22234-8223653
31 Dec 21213-8622153
30 Sep 21205-8821255
30 Jun 21198-9621455
31 Mar 21182-9219754
31 Dec 20181-10120158
30 Sep 20174-11520760
30 Jun 20165-12720466
31 Mar 20166-15122768
31 Dec 19155-16122669
30 Sep 19132-16621368
30 Jun 19108-19121567
31 Mar 1998-18219968
31 Dec 1897-17619266
30 Sep 18101-18218168
30 Jun 18119-14616365
31 Mar 18128-13214866
31 Dec 17129-12915061
30 Sep 17132-11215356
30 Jun 17126-12415454
31 Mar 17114-12416042
31 Dec 16105-11014038
31 Dec 1562-608819
31 Dec 1441-756117

Quality Earnings: BONEX has a high level of non-cash earnings.

Growing Profit Margin: BONEX's current net profit margins (11.1%) are lower than last year (41%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BONEX has become profitable over the past 5 years, growing earnings by 62.2% per year.

Accelerating Growth: BONEX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BONEX had negative earnings growth (-57.6%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).


Return on Equity

High ROE: BONEX's Return on Equity (13.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies